# DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis

Study · id `cardio:ct-nct07322237` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07322237](<https://clinicaltrials.gov/study/NCT07322237>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07322237

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 400 participants.

## Technical summary

Registry record NCT07322237. Randomized; quadruple masking; primary purpose treatment. Start 2026-04-01 (actual); primary completion 2029-01-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT07322237, source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)
- Started: 2026-04-01 (actual) (ClinicalTrials.gov record NCT07322237, source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)
- Primary completion: 2029-01-30 (anticipated) (ClinicalTrials.gov record NCT07322237, source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)
- Completion: 2029-06-30 (anticipated) (ClinicalTrials.gov record NCT07322237, source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)
- Countries: India (ClinicalTrials.gov record NCT07322237, source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07322237-2026-05-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis
- Acronym: DICE
- Condition: Cirrhotic Cardiomyopathy
- Condition: Empagliflozin
- Condition: Cardiometabolic Risk Factors
- Condition: Cirrhosis
- Intervention (Drug): Empagliflozin + Carvedilol
- Intervention (Drug): Carvedilol
- Lead sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with mildly reduced or preserved ejection fraction (`cardio:hfpef`)
- Registry intervention name matches this record: Carvedilol (`cardio:carvedilol`)
- Registry lists this organization as the lead sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh (`cardio:org-post-graduate-institute-of-medical-education-and-research-6933b6`)

## Provenance

Content hash: 35a30ab5cdc07f2be821113a454e4bb28832f7271a46c04e1eed2399e8e4ef2a
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
